Real-world utilization of Cenobamate as adjunct therapy in office-based neurology: practical tips and insights for titration

IntroductionEpilepsy poses significant management challenges, particularly in patients with refractory epilepsy where conventional antiseizure medications (ASMs) are ineffective. Cenobamate (CNB), a recently approved third-generation ASM, has shown unprecedented efficacy as an adjunctive therapy in...

Full description

Saved in:
Bibliographic Details
Main Authors: Patrick M. House, Lars Wiese
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Neurology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2025.1558614/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849331514079182848
author Patrick M. House
Lars Wiese
author_facet Patrick M. House
Lars Wiese
author_sort Patrick M. House
collection DOAJ
description IntroductionEpilepsy poses significant management challenges, particularly in patients with refractory epilepsy where conventional antiseizure medications (ASMs) are ineffective. Cenobamate (CNB), a recently approved third-generation ASM, has shown unprecedented efficacy as an adjunctive therapy in clinic-based practice. However, to date, its use by office-based neurologists in Germany remains relatively limited. One reason for this is its perceived complexity and false perception as a medication of last resort. This study focuses on the logistics of German care pathways, CNB titration, and ASM combinations in a first cohort of office-based outpatients. It also gives a glimpse into which ASMs are being used in the office-based setting in comparison to population and clinic-based data sources.MethodsThe cohort comprised 55 patients from two office-based outpatient practices (Niedergelassene) in Berlin (n = 25) and Hamburg (n = 30). All patients had a history of refractory epilepsy despite optimal treatment with existing ASMs. Patients were initiated on CNB from the month of approval (June 2021) to March 2023. Data on prior ASM usage were collated alongside clinical data, which included seizure frequency and drug load reduction outcomes to March 2025.ResultsPrior to CNB initiation, patients at both office-based practices had similar levels of 1–2 concurrent ASMs (Berlin 80%; Hamburg 77%). The most common ASMs were voltage-gated sodium channel blockers (VGSC), Levetiracetam (LEV)/Brivaracetam (BRV) synaptic vesicle protein 2A (SV2A) inhibitors, and Perampanel (PER). CNB titration was configured into a quarterly office-based outpatient schedule. All patients had seizure reductions in-line with published and real-world evidence, and were compliant.Discussion and conclusionCNB is a valuable adjunctive therapy suitable for refractory epilepsy outpatients attending office-based neurologists. A slow titration schedule helped mitigate most side effects. Despite differences to clinic-based practice, in office-based outpatient practice CNB can be broadly used. It can be prescribed to patients on conventional therapy who are still having seizures and have failed two or more other ASMs. By reporting experiences of CNB titration, seizure, and drug load reduction outcomes in office-based neurology, this study will give German office-based outpatient neurologists evidence to support both CNB and other third-generation ASM use in their practice.
format Article
id doaj-art-e431f2b846934dd4acfc734681301c2c
institution Kabale University
issn 1664-2295
language English
publishDate 2025-06-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Neurology
spelling doaj-art-e431f2b846934dd4acfc734681301c2c2025-08-20T03:46:33ZengFrontiers Media S.A.Frontiers in Neurology1664-22952025-06-011610.3389/fneur.2025.15586141558614Real-world utilization of Cenobamate as adjunct therapy in office-based neurology: practical tips and insights for titrationPatrick M. House0Lars Wiese1Epileptologicum Hamburg, Hamburg, GermanyZentrum für Neurologie in Berlin-Charlottenburg, Berlin, GermanyIntroductionEpilepsy poses significant management challenges, particularly in patients with refractory epilepsy where conventional antiseizure medications (ASMs) are ineffective. Cenobamate (CNB), a recently approved third-generation ASM, has shown unprecedented efficacy as an adjunctive therapy in clinic-based practice. However, to date, its use by office-based neurologists in Germany remains relatively limited. One reason for this is its perceived complexity and false perception as a medication of last resort. This study focuses on the logistics of German care pathways, CNB titration, and ASM combinations in a first cohort of office-based outpatients. It also gives a glimpse into which ASMs are being used in the office-based setting in comparison to population and clinic-based data sources.MethodsThe cohort comprised 55 patients from two office-based outpatient practices (Niedergelassene) in Berlin (n = 25) and Hamburg (n = 30). All patients had a history of refractory epilepsy despite optimal treatment with existing ASMs. Patients were initiated on CNB from the month of approval (June 2021) to March 2023. Data on prior ASM usage were collated alongside clinical data, which included seizure frequency and drug load reduction outcomes to March 2025.ResultsPrior to CNB initiation, patients at both office-based practices had similar levels of 1–2 concurrent ASMs (Berlin 80%; Hamburg 77%). The most common ASMs were voltage-gated sodium channel blockers (VGSC), Levetiracetam (LEV)/Brivaracetam (BRV) synaptic vesicle protein 2A (SV2A) inhibitors, and Perampanel (PER). CNB titration was configured into a quarterly office-based outpatient schedule. All patients had seizure reductions in-line with published and real-world evidence, and were compliant.Discussion and conclusionCNB is a valuable adjunctive therapy suitable for refractory epilepsy outpatients attending office-based neurologists. A slow titration schedule helped mitigate most side effects. Despite differences to clinic-based practice, in office-based outpatient practice CNB can be broadly used. It can be prescribed to patients on conventional therapy who are still having seizures and have failed two or more other ASMs. By reporting experiences of CNB titration, seizure, and drug load reduction outcomes in office-based neurology, this study will give German office-based outpatient neurologists evidence to support both CNB and other third-generation ASM use in their practice.https://www.frontiersin.org/articles/10.3389/fneur.2025.1558614/fullCenobamaterefractory epilepsyseizure freedomantiseizure medicationneurologistepileptologist
spellingShingle Patrick M. House
Lars Wiese
Real-world utilization of Cenobamate as adjunct therapy in office-based neurology: practical tips and insights for titration
Frontiers in Neurology
Cenobamate
refractory epilepsy
seizure freedom
antiseizure medication
neurologist
epileptologist
title Real-world utilization of Cenobamate as adjunct therapy in office-based neurology: practical tips and insights for titration
title_full Real-world utilization of Cenobamate as adjunct therapy in office-based neurology: practical tips and insights for titration
title_fullStr Real-world utilization of Cenobamate as adjunct therapy in office-based neurology: practical tips and insights for titration
title_full_unstemmed Real-world utilization of Cenobamate as adjunct therapy in office-based neurology: practical tips and insights for titration
title_short Real-world utilization of Cenobamate as adjunct therapy in office-based neurology: practical tips and insights for titration
title_sort real world utilization of cenobamate as adjunct therapy in office based neurology practical tips and insights for titration
topic Cenobamate
refractory epilepsy
seizure freedom
antiseizure medication
neurologist
epileptologist
url https://www.frontiersin.org/articles/10.3389/fneur.2025.1558614/full
work_keys_str_mv AT patrickmhouse realworldutilizationofcenobamateasadjuncttherapyinofficebasedneurologypracticaltipsandinsightsfortitration
AT larswiese realworldutilizationofcenobamateasadjuncttherapyinofficebasedneurologypracticaltipsandinsightsfortitration